Antibody-Based Therapy for Enterococcal Catheter-Associated Urinary Tract Infections
Related Experiment Video
Updated: Mar 12, 2026

An In Vitro Bladder Model of Catheter-Associated Urinary Tract Infection
Published on: June 24, 2025
Ana L Flores-Mireles1, Jennifer N Walker1, Aaron Potretzke2
1Department of Molecular Microbiology and Center for Women's Infectious Disease Research, Washington University School of Medicine, Saint Louis, Missouri, USA.
Abstract:
Gram-positive bacteria in the genus Enterococcus are a frequent cause of catheter-associated urinary tract infection (CAUTI), a disease whose treatment is increasingly challenged by multiantibiotic-resistant strains. We have recently shown that E. faecalis uses the Ebp pilus, a heteropolymeric surface fiber, to bind the host protein fibrinogen as a critical step in CAUTI pathogenesis. Fibrinogen is deposited on catheters due to catheter-induced inflammation and is recognized by the N-terminal domain of EbpA (EbpANTD), the Ebp pilus's adhesin. In a murine model, vaccination with EbpANTD confers significant protection against CAUTI. Here, we explored the mechanism of protection using passive transfer of immune sera to show that antisera blocking EbpANTD-fibrinogen interactions not only is prophylactic but also can act therapeutically to reduce bacterial titers of an existing infection. Analysis of 55 clinical CAUTI, bloodstream, and gastrointestinal isolates, including E. faecalis, E. faecium, and vancomycin-resistant enterococci (VRE), revealed a diversity of levels of EbpA expression and fibrinogen-binding efficiency in vitro Strikingly, analysis of 10 strains representative of fibrinogen-binding diversity demonstrated that, irrespective of EbpA levels, EbpANTD antibodies were universally protective. The results indicate that, despite diversity in levels of fibrinogen binding, strategies that target the disruption of EbpANTD-fibrinogen interactions have considerable promise for treatment of CAUTI.
Importance:
Urinary catheterization is a routine medical procedure, and it has been estimated that 30 million Foley catheters are used annually in the United States. Importantly, placement of a urinary catheter renders the patient susceptible to developing a catheter-associated urinary tract infection, accounting for 1 million cases per year. Additionally, these infections can lead to serious complications, including bloodstream infection and death. Enterococcus strains are a common cause of these infections, and management of enterococcal infections has been more difficult in recent years due to the development of antibiotic resistance and the ability of strains to disseminate, resulting in a major threat in hospital settings. In this study, we developed an antibiotic-sparing treatment that is effective against diverse enterococcal isolates, including vancomycin-resistant enterococci, during catheter-associated urinary tract infections.
Insights
Antibodies targeting the Enterococcus faecalis EbpA adhesin can prevent and treat catheter-associated urinary tract infections (CAUTIs). This approach shows promise against multi-drug resistant strains, offering an alternative to antibiotics.
Area of Science:
- Microbiology
- Immunology
- Infectious Diseases
Background:
- Catheter-associated urinary tract infections (CAUTIs) are common and difficult to treat due to multi-drug resistant Enterococcus strains.
- Enterococcus faecalis uses the Ebp pilus adhesin (EbpA) to bind host fibrinogen, a key step in CAUTI pathogenesis.
- Previous studies showed vaccination with EbpA's N-terminal domain (EbpANTD) protects against CAUTI in a murine model.
Purpose of the Study:
- To investigate the mechanism of protection conferred by EbpANTD antibodies.
- To evaluate the therapeutic potential of blocking EbpANTD-fibrinogen interactions.
- To assess the efficacy of EbpANTD antibodies against diverse clinical Enterococcus isolates.
Main Methods:
- Passive transfer of immune sera in a murine CAUTI model.
- Analysis of EbpA expression and fibrinogen-binding efficiency in 55 clinical isolates.
- Testing the protective effect of EbpANTD antibodies across a range of clinical strains.
Main Results:
- Antisera blocking EbpANTD-fibrinogen interactions demonstrated both prophylactic and therapeutic effects, reducing bacterial titers.
- Clinical isolates showed diverse levels of EbpA expression and fibrinogen-binding.
- EbpANTD antibodies provided universal protection irrespective of EbpA expression levels or binding efficiency.
Conclusions:
- Disrupting EbpANTD-fibrinogen interactions is a promising therapeutic strategy for CAUTIs.
- This approach offers an antibiotic-sparing treatment effective against a wide range of Enterococcus strains, including VRE.
- Targeting the adhesin-host protein interaction provides a broadly applicable method for combating CAUTI.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urine Studies II: Urine Culture and Sensitivity Test
Urinary Tract Infection IV: Nursing Management
Urinary Tract Infection II: Pathophysiology
Urinary Tract Infection I: Introduction

